Suzanne L Topalian, MD
Disclosures: Consulting Fee-AstraZeneca (Relationship has ended)|Consulting Fee-Dragonfly Therapeutics|Consulting Fee-Five Prime Therapeutics (Relationship has ended)|Consulting Fee-Immunocore|Other: Spouse consultant-Amgen|Other: Spouse consultant-Bristol-Myers Squibb|Other: Spouse consultant-Compugen|Other: Spouse consultant-Janssen|Other: Spouse consultant.-RAPT|Other: Spouse consultant. -Shattuck Labs|Other: Spouse consultant. -Tempest Therapeutics|Other: Spouse consultant. -Tizona|Other: Spouse consultant. -WindMIL (Relationship has ended)|Grant or research support-Bristol-Myers Squibb|Other: Spouse research grant support.-Compugen|Other: Spouse research grant support.-Enara Bioi|Stocks or stock options, excluding diversified mutual funds-Dragonfly Therapeutics|Other: Spouse stock or stock options.-DNAtrix|Other: Spouse stock or stock options. -Dracen|Other: Spouse stock or stock options.-Enara Bio|Other: Spouse stock or stock options. -ManaT Bio|Other: Spouse stock or stock options.-RAPT|Other: Spouse stock or stock options. -Tieza|Other: Spouse stock or stock options.-Tizona (Relationship has ended)|Other: Spouse stock or stock options.-TRex Bio|Other: Spouse stock or stock options.-WindMIL (Relationship has ended)|Other: Spouse, royalties or patent beneficiary.-Bristol-Myers Squibb|Other: Spouse, royalties or patent beneficiary. -Immunomic Therapeutics|Other: Spouse, royalties or patent beneficiary.-WindMIL (Relationship has ended) - 03/30/2022






Dr. Topalian is the Bloomberg~Kimmel Professor of Cancer Immunotherapy at Johns Hopkins University School of Medicine.  She is a physician-scientist whose studies have been foundational in developing cancer immunotherapyShe trained at Tufts University School of Medicine, Thomas Jefferson University Hospital, and the National Cancer Institute, after which she was a Senior Investigator at the NCI.  She joined Johns Hopkins in 2006, leading its Melanoma Program.  Her research focuses on manipulating immune checkpoints such as PD-1 in cancer therapy. She was named one of Nature’s 10 in 2014, received ASCO’s Karnofsky Award in 2015 and the Taubman Prize in 2016, and was elected to the National Academy of Medicine in 2017, for landmark discoveries in immunotherapy.  Her work has opened new avenues of investigation and supported the establishment of immunotherapy as a pillar of oncology.